ANIP
ANI Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ANIP
Ani Pharmaceuticals, Inc.
A diversified biopharmaceutical company that develops and manufactures branded and generic prescription pharmaceuticals
210 Main Street West, Baudette, Minnesota 56623
--
ANI Pharmaceuticals, Inc., was founded in Delaware in April 2001. The Company is an integrated specialty pharmaceutical company dedicated to delivering value to the Company's customers by developing, manufacturing and selling high-quality branded and generic prescription drugs. The company focuses on niche and high-entry opportunities, including controlled substances, anticancer (oncolytic drugs), hormones and steroids, and complex formulations. The company's two pharmaceutical plants in Baudette, Minnesota are capable of producing oral solid dose products, as well as liquid and topical, controlled substances and effective products that must be manufactured in a fully enclosed environment. The company's strategy is to use its assets to develop, acquire, manufacture and sell branded and generic specialty prescription drugs.
Earnings Call
Q1/2025
Estimate EPS-0.06
Actual EPS1.7
Estimate Revenue180.69M
Actual Revenue197.12M
ANI Pharmaceuticals' Q1 2025: Contradictions Unveiled on ILUVIEN, YUTIQ, and Cortrophin Growth Dynamics
May 20,2025 03:57
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.42
Actual EPS1.8
Estimate Revenue190.11M
Actual Revenue211.37M
ANI Pharmaceuticals' Q2 2025: Unpacking Contradictions in Cortrophin Growth and Market Dynamics
Aug 08,2025 04:07
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ANIP has released its 2025 Q3 earnings. EPS was reported at 2.04, versus the expected 1.77, beating expectations. The chart below visualizes how ANIP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ANIP has released its 2025 Q3 earnings report, with revenue of 227.81M, reflecting a YoY change of 53.58%, and net profit of 26.62M, showing a YoY change of 210.14%. The Sankey diagram below clearly presents ANIP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
